Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Editas Medicine (NQ: EDIT ) 3.380 +0.180 (+5.62%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Editas Medicine < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session September 25, 2023 Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. Via Benzinga Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer September 25, 2023 From Editas Medicine, Inc. Via GlobeNewswire Analyst Expectations for Editas Medicine's Future August 29, 2023 Via Benzinga Expert Ratings for Editas Medicine August 03, 2023 Via Benzinga Is Editas Medicine Stock a Buy Now? June 28, 2023 The fortunes of this once-promising biotech company have changed in the past year. Via The Motley Fool Are Gene Therapy Stocks The Market's Next Big Winners? September 25, 2023 Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence 1 Gene Editing Stock to Buy Now, and 1 to Sell September 23, 2023 Target markets matter. So does having the cash to get to them. Via The Motley Fool Editas Medicine Announces Upcoming Investor Events August 30, 2023 From Editas Medicine, Inc. Via GlobeNewswire These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street August 23, 2023 Is the Street's optimism justified here? Via The Motley Fool Editas Medicine Announces Second Quarter 2023 Results and Business Updates August 02, 2023 From Editas Medicine, Inc. Via GlobeNewswire What 6 Analyst Ratings Have To Say About Editas Medicine June 13, 2023 Via Benzinga Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization July 27, 2023 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update July 26, 2023 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer July 24, 2023 From Editas Medicine, Inc. Via GlobeNewswire This 1 Problem Could Sink at Least 4 Gene-Editing Stocks June 29, 2023 Reaching profitability could be harder than investors expect. Via The Motley Fool What Is CRISPR And Why Should Your Portfolio Care? June 25, 2023 CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. Via Talk Markets After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock? June 20, 2023 It's not about to start making money anytime soon. Via The Motley Fool Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 15, 2023 Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. Via Benzinga 2 Short-Squeeze Candidates That Could Go Parabolic June 15, 2023 Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. Via The Motley Fool Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 15, 2023 U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga Editas Medicine Announces Pricing of Offering of Common Stock June 14, 2023 From Editas Medicine, Inc. Via GlobeNewswire Editas Medicine Announces Offering of Common Stock June 14, 2023 From Editas Medicine, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023 June 13, 2023 Via Benzinga 5 Stocks to Buy With Explosive 500% Potential June 12, 2023 Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. Via InvestorPlace Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders June 09, 2023 Editas Medicine Inc (NASDAQ: EDIT) annou Via Benzinga Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial June 09, 2023 From Editas Medicine, Inc. Via GlobeNewswire Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? June 06, 2023 Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. Via InvestorPlace Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia June 06, 2023 From Editas Medicine, Inc. Via GlobeNewswire Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial June 01, 2023 A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... Via Benzinga 7 Short-Squeeze Stocks Set for a May Rally May 22, 2023 While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.